Gastric Cancer Drugs Market Size, Trends, Analysis, and Outlook By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others) ), By Route of Administration (Injectable, Oral), By Distribution Channel (Offline, Online), by Region, Country, Segment, and Companies, 2024-2030
The global Gastric Cancer Drugs market size is poised to register 14.07% growth (CAGR) from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Gastric Cancer Drugs market By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others) ), By Route of Administration (Injectable, Oral), By Distribution Channel (Offline, Online).
The future of gastric cancer drugs is shaped by advancements in precision medicine, immunotherapy, and combination treatment regimens, offering new hope for patients with this aggressive malignancy. With gastric cancer being one of the leading causes of cancer-related deaths worldwide, there is an urgent need for more effective therapies that can improve survival outcomes and quality of life. Key trends include the development of targeted therapies such as HER2 inhibitors, angiogenesis inhibitors, and receptor tyrosine kinase inhibitors that aim to disrupt specific molecular pathways driving tumor growth and progression. Additionally, there is a growing interest in immunotherapy agents such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, which harness the body's immune system to recognize and attack cancer cells. Moreover, there is ongoing research into novel drug delivery systems, biomarker-driven treatment algorithms, and combination therapies involving chemotherapy, radiation therapy, and immunotherapy to overcome treatment resistance and achieve durable responses in gastric cancer patients..
Gastric Cancer Drugs Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Gastric Cancer Drugs market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Gastric Cancer Drugs survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Gastric Cancer Drugs industry.
Key market trends defining the global Gastric Cancer Drugs demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Gastric Cancer Drugs Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Gastric Cancer Drugs industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Gastric Cancer Drugs companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Gastric Cancer Drugs industry
Leading Gastric Cancer Drugs companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Gastric Cancer Drugs companies.
Gastric Cancer Drugs Market Study- Strategic Analysis Review
The Gastric Cancer Drugs market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
The Gastric Cancer Drugs industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Gastric Cancer Drugs Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Gastric Cancer Drugs Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Gastric Cancer Drugs market segments. Similarly, Strong end-user demand is encouraging Canadian Gastric Cancer Drugs companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Gastric Cancer Drugs market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Gastric Cancer Drugs Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Gastric Cancer Drugs industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Gastric Cancer Drugs market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Gastric Cancer Drugs Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Gastric Cancer Drugs in Asia Pacific. In particular, China, India, and South East Asian Gastric Cancer Drugs markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Gastric Cancer Drugs Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Gastric Cancer Drugs Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Gastric Cancer Drugs market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Gastric Cancer Drugs.
Gastric Cancer Drugs Market Company Profiles
The global Gastric Cancer Drugs market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AbbVie Inc, AROG Pharmaceuticals Inc, AstraZeneca Plc, Bayer AG, Biocon Ltd, Blueprint Medicines Corp, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celltrion Co. Ltd, Dr Reddys Laboratories Ltd, Eisai Co. Ltd, Eli Lilly and Co., F. Hoffmann La Roche Ltd, Merck KGaA, Novartis AG, Otsuka Holdings Co. Ltd, Samsung Biologics Co. Ltd, Takeda Pharmaceutical Co. Ltd, Zydus Lifesciences Ltd.
Recent Gastric Cancer Drugs Market Developments
The global Gastric Cancer Drugs market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Gastric Cancer Drugs Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
By Type
Stationary 3D and 4D Ultrasound Devices
Portable 3D and 4D Ultrasound Devices
By Display
Color Ultrasound
B/W Ultrasound
By Portability
Trolley or Cart-Based Ultrasound Systems
Compact/Handheld Ultrasound Systems
Point-of-Pare (PoC) Ultrasound Systems
By Application
Radiology or General Imaging
Obstetrics or Gynecology
Cardiology
Urology
Vascular
Orthopedic and Musculoskeletal
Pain Management
Others
By End-User
Hospitals
Surgical Centers and Diagnostic Centers
Maternity Centers
Ambulatory Care Centers
Research and Academia
Others
Geographical Segmentation:
AbbVie Inc
AROG Pharmaceuticals Inc
AstraZeneca Plc
Bayer AG
Biocon Ltd
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
Bristol Myers Squibb Co.
Celltrion Co. Ltd
Dr Reddys Laboratories Ltd
Eisai Co. Ltd
Eli Lilly and Co.
F. Hoffmann La Roche Ltd
Merck KGaA
Novartis AG
Otsuka Holdings Co. Ltd
Samsung Biologics Co. Ltd
Takeda Pharmaceutical Co. Ltd
Zydus Lifesciences Ltd
Formats Available: Excel, PDF, and PPT
The future of gastric cancer drugs is shaped by advancements in precision medicine, immunotherapy, and combination treatment regimens, offering new hope for patients with this aggressive malignancy. With gastric cancer being one of the leading causes of cancer-related deaths worldwide, there is an urgent need for more effective therapies that can improve survival outcomes and quality of life. Key trends include the development of targeted therapies such as HER2 inhibitors, angiogenesis inhibitors, and receptor tyrosine kinase inhibitors that aim to disrupt specific molecular pathways driving tumor growth and progression. Additionally, there is a growing interest in immunotherapy agents such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, which harness the body's immune system to recognize and attack cancer cells. Moreover, there is ongoing research into novel drug delivery systems, biomarker-driven treatment algorithms, and combination therapies involving chemotherapy, radiation therapy, and immunotherapy to overcome treatment resistance and achieve durable responses in gastric cancer patients..
Gastric Cancer Drugs Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Gastric Cancer Drugs market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Gastric Cancer Drugs survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Gastric Cancer Drugs industry.
Key market trends defining the global Gastric Cancer Drugs demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Gastric Cancer Drugs Market Segmentation- Industry Share, Market Size, and Outlook to 2030
The Gastric Cancer Drugs industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Gastric Cancer Drugs companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Gastric Cancer Drugs industry
Leading Gastric Cancer Drugs companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Gastric Cancer Drugs companies.
Gastric Cancer Drugs Market Study- Strategic Analysis Review
The Gastric Cancer Drugs market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
- Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
- Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
- Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
- Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.
The Gastric Cancer Drugs industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.
Gastric Cancer Drugs Country Analysis and Revenue Outlook to 2030
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.
North America Gastric Cancer Drugs Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Gastric Cancer Drugs market segments. Similarly, Strong end-user demand is encouraging Canadian Gastric Cancer Drugs companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Gastric Cancer Drugs market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Gastric Cancer Drugs Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Gastric Cancer Drugs industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Gastric Cancer Drugs market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Gastric Cancer Drugs Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Gastric Cancer Drugs in Asia Pacific. In particular, China, India, and South East Asian Gastric Cancer Drugs markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.
Latin America Gastric Cancer Drugs Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Gastric Cancer Drugs Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Gastric Cancer Drugs market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Gastric Cancer Drugs.
Gastric Cancer Drugs Market Company Profiles
The global Gastric Cancer Drugs market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AbbVie Inc, AROG Pharmaceuticals Inc, AstraZeneca Plc, Bayer AG, Biocon Ltd, Blueprint Medicines Corp, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celltrion Co. Ltd, Dr Reddys Laboratories Ltd, Eisai Co. Ltd, Eli Lilly and Co., F. Hoffmann La Roche Ltd, Merck KGaA, Novartis AG, Otsuka Holdings Co. Ltd, Samsung Biologics Co. Ltd, Takeda Pharmaceutical Co. Ltd, Zydus Lifesciences Ltd.
Recent Gastric Cancer Drugs Market Developments
The global Gastric Cancer Drugs market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Gastric Cancer Drugs Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
- Pricing Analysis
- Value Chain Analysis
- SWOT Profile
- Market Dynamics- Trends, Drivers, Challenges
- Porter’s Five Forces Analysis
- Macroeconomic Impact Analysis
- Case Scenarios- Low, Base, High
By Type
Stationary 3D and 4D Ultrasound Devices
Portable 3D and 4D Ultrasound Devices
By Display
Color Ultrasound
B/W Ultrasound
By Portability
Trolley or Cart-Based Ultrasound Systems
Compact/Handheld Ultrasound Systems
Point-of-Pare (PoC) Ultrasound Systems
By Application
Radiology or General Imaging
Obstetrics or Gynecology
Cardiology
Urology
Vascular
Orthopedic and Musculoskeletal
Pain Management
Others
By End-User
Hospitals
Surgical Centers and Diagnostic Centers
Maternity Centers
Ambulatory Care Centers
Research and Academia
Others
Geographical Segmentation:
- North America (3 markets)
- Europe (6 markets)
- Asia Pacific (6 markets)
- Latin America (3 markets)
- Middle East Africa (5 markets)
AbbVie Inc
AROG Pharmaceuticals Inc
AstraZeneca Plc
Bayer AG
Biocon Ltd
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
Bristol Myers Squibb Co.
Celltrion Co. Ltd
Dr Reddys Laboratories Ltd
Eisai Co. Ltd
Eli Lilly and Co.
F. Hoffmann La Roche Ltd
Merck KGaA
Novartis AG
Otsuka Holdings Co. Ltd
Samsung Biologics Co. Ltd
Takeda Pharmaceutical Co. Ltd
Zydus Lifesciences Ltd
Formats Available: Excel, PDF, and PPT
1. EXECUTIVE SUMMARY
1.1 Gastric Cancer Drugs Market Overview and Key Findings, 2024
1.2 Gastric Cancer Drugs Market Size and Growth Outlook, 2021- 2030
1.3 Gastric Cancer Drugs Market Growth Opportunities to 2030
1.4 Key Gastric Cancer Drugs Market Trends and Challenges
1.4.1 Gastric Cancer Drugs Market Drivers and Trends
1.4.2 Gastric Cancer Drugs Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Gastric Cancer Drugs Companies
2. GASTRIC CANCER DRUGS MARKET SIZE OUTLOOK TO 2030
2.1 Gastric Cancer Drugs Market Size Outlook, USD Million, 2021- 2030
2.2 Gastric Cancer Drugs Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. GASTRIC CANCER DRUGS MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. GASTRIC CANCER DRUGS MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Type
Stationary 3D and 4D Ultrasound Devices
Portable 3D and 4D Ultrasound Devices
By Display
Color Ultrasound
B/W Ultrasound
By Portability
Trolley or Cart-Based Ultrasound Systems
Compact/Handheld Ultrasound Systems
Point-of-Pare (PoC) Ultrasound Systems
By Application
Radiology or General Imaging
Obstetrics or Gynecology
Cardiology
Urology
Vascular
Orthopedic and Musculoskeletal
Pain Management
Others
By End-User
Hospitals
Surgical Centers and Diagnostic Centers
Maternity Centers
Ambulatory Care Centers
Research and Academia
Others
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Gastric Cancer Drugs Market, 2025
5.2 Asia Pacific Gastric Cancer Drugs Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Gastric Cancer Drugs Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Gastric Cancer Drugs Market, 2025
5.5 Europe Gastric Cancer Drugs Market Size Outlook by Type, 2021- 2030
5.6 Europe Gastric Cancer Drugs Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Gastric Cancer Drugs Market, 2025
5.8 North America Gastric Cancer Drugs Market Size Outlook by Type, 2021- 2030
5.9 North America Gastric Cancer Drugs Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Gastric Cancer Drugs Market, 2025
5.11 South America Pacific Gastric Cancer Drugs Market Size Outlook by Type, 2021- 2030
5.12 South America Gastric Cancer Drugs Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Gastric Cancer Drugs Market, 2025
5.14 Middle East Africa Gastric Cancer Drugs Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Gastric Cancer Drugs Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Gastric Cancer Drugs Market Size Outlook and Revenue Growth Forecasts
6.2 US Gastric Cancer Drugs Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Gastric Cancer Drugs Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Gastric Cancer Drugs Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Gastric Cancer Drugs Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Gastric Cancer Drugs Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Gastric Cancer Drugs Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Gastric Cancer Drugs Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Gastric Cancer Drugs Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Gastric Cancer Drugs Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Gastric Cancer Drugs Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Gastric Cancer Drugs Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Gastric Cancer Drugs Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Gastric Cancer Drugs Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Gastric Cancer Drugs Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Gastric Cancer Drugs Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Gastric Cancer Drugs Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Gastric Cancer Drugs Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Gastric Cancer Drugs Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Gastric Cancer Drugs Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Gastric Cancer Drugs Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Gastric Cancer Drugs Industry Drivers and Opportunities
7. GASTRIC CANCER DRUGS MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. GASTRIC CANCER DRUGS COMPANY PROFILES
8.1 Profiles of Leading Gastric Cancer Drugs Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
AbbVie Inc
AROG Pharmaceuticals Inc
AstraZeneca Plc
Bayer AG
Biocon Ltd
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
Bristol Myers Squibb Co.
Celltrion Co. Ltd
Dr Reddys Laboratories Ltd
Eisai Co. Ltd
Eli Lilly and Co.
F. Hoffmann La Roche Ltd
Merck KGaA
Novartis AG
Otsuka Holdings Co. Ltd
Samsung Biologics Co. Ltd
Takeda Pharmaceutical Co. Ltd
Zydus Lifesciences Ltd
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
1.1 Gastric Cancer Drugs Market Overview and Key Findings, 2024
1.2 Gastric Cancer Drugs Market Size and Growth Outlook, 2021- 2030
1.3 Gastric Cancer Drugs Market Growth Opportunities to 2030
1.4 Key Gastric Cancer Drugs Market Trends and Challenges
1.4.1 Gastric Cancer Drugs Market Drivers and Trends
1.4.2 Gastric Cancer Drugs Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Gastric Cancer Drugs Companies
2. GASTRIC CANCER DRUGS MARKET SIZE OUTLOOK TO 2030
2.1 Gastric Cancer Drugs Market Size Outlook, USD Million, 2021- 2030
2.2 Gastric Cancer Drugs Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. GASTRIC CANCER DRUGS MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. GASTRIC CANCER DRUGS MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Type
Stationary 3D and 4D Ultrasound Devices
Portable 3D and 4D Ultrasound Devices
By Display
Color Ultrasound
B/W Ultrasound
By Portability
Trolley or Cart-Based Ultrasound Systems
Compact/Handheld Ultrasound Systems
Point-of-Pare (PoC) Ultrasound Systems
By Application
Radiology or General Imaging
Obstetrics or Gynecology
Cardiology
Urology
Vascular
Orthopedic and Musculoskeletal
Pain Management
Others
By End-User
Hospitals
Surgical Centers and Diagnostic Centers
Maternity Centers
Ambulatory Care Centers
Research and Academia
Others
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Gastric Cancer Drugs Market, 2025
5.2 Asia Pacific Gastric Cancer Drugs Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Gastric Cancer Drugs Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Gastric Cancer Drugs Market, 2025
5.5 Europe Gastric Cancer Drugs Market Size Outlook by Type, 2021- 2030
5.6 Europe Gastric Cancer Drugs Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Gastric Cancer Drugs Market, 2025
5.8 North America Gastric Cancer Drugs Market Size Outlook by Type, 2021- 2030
5.9 North America Gastric Cancer Drugs Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Gastric Cancer Drugs Market, 2025
5.11 South America Pacific Gastric Cancer Drugs Market Size Outlook by Type, 2021- 2030
5.12 South America Gastric Cancer Drugs Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Gastric Cancer Drugs Market, 2025
5.14 Middle East Africa Gastric Cancer Drugs Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Gastric Cancer Drugs Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Gastric Cancer Drugs Market Size Outlook and Revenue Growth Forecasts
6.2 US Gastric Cancer Drugs Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Gastric Cancer Drugs Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Gastric Cancer Drugs Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Gastric Cancer Drugs Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Gastric Cancer Drugs Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Gastric Cancer Drugs Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Gastric Cancer Drugs Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Gastric Cancer Drugs Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Gastric Cancer Drugs Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Gastric Cancer Drugs Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Gastric Cancer Drugs Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Gastric Cancer Drugs Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Gastric Cancer Drugs Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Gastric Cancer Drugs Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Gastric Cancer Drugs Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Gastric Cancer Drugs Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Gastric Cancer Drugs Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Gastric Cancer Drugs Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Gastric Cancer Drugs Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Gastric Cancer Drugs Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Gastric Cancer Drugs Industry Drivers and Opportunities
7. GASTRIC CANCER DRUGS MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. GASTRIC CANCER DRUGS COMPANY PROFILES
8.1 Profiles of Leading Gastric Cancer Drugs Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
AbbVie Inc
AROG Pharmaceuticals Inc
AstraZeneca Plc
Bayer AG
Biocon Ltd
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
Bristol Myers Squibb Co.
Celltrion Co. Ltd
Dr Reddys Laboratories Ltd
Eisai Co. Ltd
Eli Lilly and Co.
F. Hoffmann La Roche Ltd
Merck KGaA
Novartis AG
Otsuka Holdings Co. Ltd
Samsung Biologics Co. Ltd
Takeda Pharmaceutical Co. Ltd
Zydus Lifesciences Ltd
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
